Avalo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases with significant unmet needs. The company targets the IL-1β pathway, a central driver of inflammation, through its lead asset, abdakibart (AVTX-009), a humanized monoclonal antibody currently in a Phase 2 LOTUS trial for hidradenitis suppurativa, a chronic inflammatory skin condition. Avalo Therapeutics Inc. is exploring the potential of AVTX-009 in additional immune-mediated indications to address broader patient populations. Founded in 2011 and headquartered in Wayne, Pennsylvania, the company focuses on advancing novel therapeutics driven by scientific innovation and compassion for those affected by chronic inflammatory conditions. Its pipeline emphasizes best-in-class medicines to transform lives in areas lacking effective therapies, operating within the health technology sector to develop and potentially commercialize targeted biologics for immune dysregulation.